Tuesday Aug 19
Response to Letter Regarding, "Administration of a Loading Dose Has...
The novel antiplatelet agent, ticagrelor, has several advantages over the long-standing clopidogrel, as the virtual absence of nonresponders and the more powerful platelet inhibition.
Tuesday Aug 19
AstraZeneca says DOJ closes probe into drug trial
British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.
Tuesday Aug 19
Top News: Pound Falls To Four-Month Low As Uk Inflation Slows To 1.6%
BHP Billiton PLC confirmed that it will demerge its aluminium, coal, manganese, nickel and silver assets into a new company, pledging to cut costs and improve the productivity of its remaining businesses in an attempt to boost shareholder returns.
Mon Aug 18, 2014
Letter by Zhang Regarding Article, "Early Dual Versus Mono...
I have read "Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack: An Updated Systematic Review and Meta-Analysis" by Wong and colleagues with great interest.
Wed Aug 13, 2014
Clopidogrel discontinuation within the first year after coronary...
The impact of adherence to the recommended duration of dual antiplatelet therapy after first generation drug-eluting stent implantation is difficult to assess in real-world settings and limited data are available.
Sat Aug 09, 2014
San Diego NewsCape
Carotid angioplasty and stenting
Carotid angioplasty is a procedure that opens clogged arteries to prevent or treat stroke.
Extending patent protections to discover the next life-saving drugs
At the end of last year, Eli Lilly's mega-blockbuster antidepressant Cymbalta went off patent.
Wed Aug 06, 2014
[Research Articles] Optimizing human apyrase to treat arterial...
In patients with acute myocardial infarction undergoing reperfusion therapy to restore blood flow through blocked arteries, simultaneous inhibition of platelet P2Y12 receptors with the current standard of care neither completely prevents recurrent thrombosis nor provides satisfactory protection against reperfusion injury.
Tue Aug 05, 2014
In-Hospital Switching Between Clopidogrel and Prasugrel Among...
From the Terrence Donnelly Heart Center, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada ; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT ; Duke Clinical Research Institute, Durham, NC ; Division of Cardiovascular Medicine, ... (more)
Thu Jul 24, 2014
Medical News Today
Heart patients in England and Wales offered more choice of therapies...
Revised guidance from the National Institute for Health and Care Excellence , recommends once-daily, oral antiplatelet prasugrel , in combination with aspirin , as a cost-effective option when compared to generic clopidogrel, for a wider group of acute coronary syndrome patients having primary or delayed percutaneous coronary intervention .1 ... (more)